The Quantellect read.As of Nov 19, 2026, 14 active firms cover Nurix Therapeutics Inc: 14 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $25.00 to $45.00, a moderate spread. The average target of $34.71 sits 146% above the current $14.11. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.59 next quarter toward $-1.28 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 active firms
Buy
Strong Buy00%
Buy14100%
Neutral00%
Sell00%
Strong Sell00%
Based on 14 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$34.71
+146.0% upside
Average target across 14 active firms as of Nov 19, 2026 vs $14.11 current
Highest Target$45.00
Average Target$34.71
Lowest Target$25.00
Detailed analyst forecasts for NRIX
Showing 1–13 of 13 named analysts shown · 14 active firms in the rating projection
As of Nov 19, 2026, 14 of 14 active firms rate NRIX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NRIX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.59
Range $-0.59 – $-0.59 · 1 analysts · -25% YoY
Next period, 1 analysts expect Nurix Therapeutics Inc to earn $-0.59 a share (range $-0.59 – $-0.59), versus $-0.79 a year earlier. Full-year consensus is $3.02, growing to $-1.28 the year after.
REVENUE · NEXT QUARTER
$15.0M
Range $15.0M – $15.0M · 1 analysts · +140% YoY
Revenue is expected to reach $15.0M (range $15.0M – $15.0M), +139.9% year-over-year. Full-year consensus is $744.8M, rising to $123.2M next year.
Top analysts covering Nurix Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NRIX.
#1
Joel Beatty
Baird · Rank #71
Buy
$36.00+155.1% to target
Overall win rate
50%
+ Follow
#2
Peter Lawson
Barclays · Rank #89
Buy
$31.00+119.7% to target
Overall win rate
45%
+ Follow
#3
Roger Song
Jefferies · Rank #122
Buy
$45.00+218.9% to target
Overall win rate
43%
+ Follow
#4
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$36.00+155.1% to target
Overall win rate
42%
+ Follow
#5
Terence Flynn
Morgan Stanley · Rank #222
Buy
$38.00+169.3% to target
Overall win rate
36%
+ Follow
NRIX stock forecast FAQ
What is NRIX's average 12-month price target?+
The 14 active firms with a live target average $34.71 for Nurix Therapeutics Inc over the next 12 months, ranging from a $45.00 high to a $25.00 low, as of Nov 19, 2026.
Is NRIX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 14 active firms as of Nov 19, 2026, 14 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for NRIX?+
The Street-high target is $45.00 (Jefferies), and the Street-low is $25.00 (Wells Fargo). The average of all 14 active-firm targets is $34.71.
How many active Wall Street firms cover NRIX?+
14 active firms have a recognized rating on Nurix Therapeutics Inc as of Nov 19, 2026, and 14 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NRIX?+
Among analysts who currently cover NRIX, Joel Beatty of Baird has the strongest overall Quantellect track record (Rank #71). Their current call is Buy with a $36.00 target.
What is Nurix Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.59 per share (range $-0.59 – $-0.59) across 1 analysts. Full-year EPS is projected at $3.02, rising to $-1.28 the following year.
How much revenue is Nurix Therapeutics Inc expected to report next quarter?+
Consensus revenue is $15.0M (range $15.0M – $15.0M). Full-year revenue is projected at $744.8M, growing to $123.2M next year.
Have analysts been upgrading or downgrading NRIX lately?+
As of Nov 19, 2026, 14 of 14 active firms rate NRIX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NRIX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.